RA
Rosalind Advisors Portfolio holdings
AUM
$274M
1-Year Est. Return
82.13%
This Fund
S&P 500
1 Year Est. Return
+82.13%
AUM
$274M
AUM Growth
-$8.51M
(-3%)
Holding
42
Top Buys
| 1 | +$12M | |
| 2 | +$4.49M | |
| 3 | +$4.41M | |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$3.86M |
| 5 |
Xeris Biopharma Holdings
XERS
|
+$2.49M |
Top Sells
| 1 | +$14.2M | |
| 2 | +$12.7M | |
| 3 | +$10.7M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$9.52M |
| 5 |
Fractyl Health
GUTS
|
+$7.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neuraxis
NRXS
$63.9M
| $1.04M | 0.38% |
+286,138
|
|
||
27
Kura Oncology
KURA
$760M
| $1.04M | 0.38% |
100,000
|
|
||
|
28
Fractyl Health
GUTS
$72M
| $849K | 0.31% |
385,731
-4,614,269
|
|
||
29
Biofrontera
BFRI
$10.6M
| $650K | 0.24% |
1,140,764
|
|
||
|
ATXS
30
DELISTED
Astria Therapeutics
ATXS
| – | – |
-1,542,520
|
|
||
31
Anavex Life Sciences
AVXL
$411M
| – | – |
0
|
|
||
|
32
IDEAYA Biosciences
IDYA
$2.83B
| – | – |
-350,000
|
|
||
33
iShares S&P 100 ETF
OEF
$28.5B
| – | – |
0
|
|
||
34
Invesco QQQ Trust
QQQ
$397B
| – | – |
0
|
|
||
35
uniQure
QURE
$974M
| – | – |
-125,000
|
|
||
36
Rezolute
RZLT
$307M
| – | – |
-1,807,202
|
|
||
37
State Street SPDR S&P 500 ETF Trust
SPY
$699B
| – | – |
0
|
|
||
38
Scholar Rock
SRRK
$4.52B
| – | – |
0
|
|
||
39
Viking Therapeutics
VKTX
$3.91B
| – | – |
0
|
|
||
|
VRNA
40
DELISTED
Verona Pharma
VRNA
| – | – |
-100,000
|
|
||
41
VistaGen Therapeutics
VTGN
$23.2M
| – | – |
0
|
|
||
42
State Street SPDR NYSE Technology ETF
XNTK
$1.52B
| – | – |
0
|
|